Biosimilars: What Differences Between the EU and the U.S.?

Generic versions of off-patent biological products are set to become more prominent fixtures of the pharmaceutical landscape. Hogan & Hartson partners provide contrasting perspectives on the regulatory systems governing biosimilar products in two of the world's major pharmaceutical markets.


Download PDF Share Back To Listing
Loading data